Board of Directors

Don Hayden
Chairman of the Board

Don Hayden brings experience and insight to the REGENXBIO Board. Mr. Hayden had a highly successful 25-year career with Bristol-Myers Squibb Company and continues to hold key roles at a number of entrepreneurial pharmaceutical and biotech companies.

At Bristol-Myers Squibb, he served as president of Global Pharmaceuticals; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group; president of Oncology and Immunology; and senior vice president for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, he has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals, Nora Therapeutics, and Dimension Therapeutics.

Mr. Hayden received an M.B.A. from Indiana University and his undergraduate degree from Harvard University.

 

Ken Mills
Board Member, President and Chief Executive Officer
Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. He was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company’s operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance, and accounting activities. Prior to his tenure at Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology.
Allan Fox
Board Member

Allan Fox is the founding partner of FOXKISER, a nationally recognized firm specializing in biomedical research and development, law and public policy. He has created and built numerous ventures in both the public and private sectors. Mr. Fox specializes in identifying business opportunities and improving competitive market position in highly regulated industries, particularly health care.

Before forming FOXKISER, Mr. Fox established the Washington office of the law firm of Kaye, Scholer, Fierman, Hays & Handler. While in the public sector, he served as Chief of Staff and Chief Legislative Assistant to U.S. Senator Jacob K. Javits of New York. He also served as Chief Counsel to the U.S. Senate Health and Scientific Research Subcommittee, chaired by Senator Edward M. Kennedy. Mr. Fox was a Fellow in Law, Science and Medicine at Yale Law School where he received an LL.M. degree. Mr. Fox also holds a J.D. and B.A. from Temple University.

Daniel Abdun-Nabi, J.D., LL.M.

Independent Board Member

Mr. Abdun-Nabi has served as President and Chief Executive Officer of Emergent BioSolutions Inc. since April 2012. Since joining Emergent in 2004, he has held several senior leadership positions including Chief Operating Officer and General Counsel. Prior to joining Emergent, Mr. Abdun-Nabi served as General Counsel for IGEN International, Inc., and as Senior Vice President - Legal Affairs, General Counsel and Secretary at North American Vaccine, Inc.

Mr. Abdun-Nabi received a Master of Laws in taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst.

Luke M. Beshar

Independent Board Member

Mr. Beshar was Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals until February 2015 when the company was sold to Shire plc.  He joined NPS Pharmaceuticals in 2007 and at various points during his tenure was responsible for financial management, investor relations, information technology, technical operations, supply-chain management, corporate development, alliance management, project management, contracts & outsourcing, and facilities. Prior to joining NPS, Mr. Beshar served as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a global life sciences company. Mr. Beshar began his career with Arthur Andersen & Co. and is a certified public accountant. He obtained his bachelor's degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.
Jerry Karabelas, Ph.D.
Independent Board Member

Dr. Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. Dr. Karabelas was also Executive Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and strategic marketing. Most recently, Dr. Karabelas has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc. and SkyePharma PLC. He currently chairs the boards of Inotek and Polyphor, AG and is a partner at Care Capital. Dr. Karabelas holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy.

David Stump, M.D.

Independent Board Member

Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc. (HGS) and joined the company in 1999. Prior to joining HGS, he held roles of increasing responsibility at Genentech, Inc. from 1989 to 1999, most recently as Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. He earned an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa. He is currently a member of the Board of Directors of Sunesis Pharmaceuticals, Inc., MacroGenics, Inc. and Portola Pharmaceuticals, Inc. and a member of the Board of Trustees of Earlham College.

Daniel Tassé

Independent Board Member

Mr. Tassé is Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc. Previously, Mr. Tassé was Chairman and Chief Executive Officer of Ikaria, Inc., prior to its acquisition by Mallinckrodt Pharmaceuticals. He has also held leadership roles at Baxter International Inc. and GlaxoSmithKline plc.

Mr. Tassé earned a B.S. in biochemistry from the University of Montreal. He currently serves as a member of the boards of directors at Bellerophon Therapeutics, Inc., and Indivior PLC. Mr. Tassé has previously been a member of the Healthcare Leadership Council, the Health Section Governing Board of the Biotechnology Innovation Organization (BIO) and the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).